Certa Therapeutics Announces International Non-Proprietary Name for its First-in-class GPR68 Inhibitor Asengeprast (FT011)
Melbourne, Australia 16 September 2024: Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with fibrotic diseases, today announces that its lead candidate FT011 has been granted the International Non-Proprietary Name (INN) of ‘asengeprast’ by the World Health Organisation (WHO). Commonly known as a generic name, an INN is a globally recognised, […]
ABSTRACT: FT011 for the treatment of Systemic Sclerosis. Results from a Phase II study.
Authors: Christopher P. Denton1, Wendy Stevens2, Nicole Kruger3, Michelle Papadimitriou3,4, Fay Khong3,4, Michelle Bradney3, Darren J. Kelly3,4, Robert Lafyatis5. 1Centre for Rheumatology, Royal Free Hospital, London, United Kingdom, 2Department of Rheumatology, St Vincent’s Hospital, Melbourne, Vic., Australia, 3Certa Therapeutics Pty Ltd, Melbourne Vic., Australia, 4Department of Medicine, Melbourne University, Melbourne Vic. Australia, 5Division of Rheumatology, […]